Published in the Journal of Clinical Oncology

New data continues to lend support to the increasing role of biomarker analysis and molecular profiling in cancer diagnosis and treatment. A study, published in the Journal of Clinical Oncology, confirmed that there are FDA-approved agents with literature support that can successfully be used against targets in refractory tumors, improving outcomes in cancers where no standard-of-care options exists:

• Overall improvement in progression-free survival (PFS), using molecular profiling to guide therapy, was seen in 27% of patients.
• Patients with a PFS ratio of ≥1.3 had better survival than the total population, suggesting the outcomes were significant, durable and impacted overall survival in a very sick patient population.

1. Von Hoff, D., et al. Pilot Study Using Molecular Profiling of Patient’s Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. J Clin Oncol. 20;28(33):4877-83. Epub 2010 Oct 4.

Learn more about the innovation behind evidence-based tumor profiling at CarisMolecularIntelligence.com.

Or learn more about the Caris Registry.

Molecular Intelligence^™ Service, from Caris Life Sciences^®, provides evidence-based tumor information that associates biomarker status to agents with potential clinical benefit or potential lack of clinical benefit. Agents associated with clinical benefit are presented based on NCCN Compendium^™ inclusion, relevance of tumor type, level of published evidence and strength of biomarker expression. Report information must be considered in conjunction with all other relevant information in respect of a given patient before determining the appropriate course of treatment. The selection of agents for re-treatment from prior chemotherapy regimens lies with the treating physician and must be done with careful consideration. Caris Molecular Intelligence Service was developed and its performance characteristics were determined by Caris Life Sciences, a medical laboratory CLIA-certified in compliance with the U.S. Clinical Laboratory Amendment Act of 1988 and all relevant U.S. state regulations. Caris Molecular Intelligence Service has not been approved by the United States Food and Drug Administration.